Palbociclib
Cyclin-Dependent Kinase (Cdk) Inhibitors
Sold as IBRANCE
- Drug class
- Cyclin-Dependent Kinase (Cdk) Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 24
Overview
Palbociclib is an active pharmaceutical ingredient in the Cyclin-Dependent Kinase (Cdk) Inhibitors group (L01EF). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 14 | February 27, 2026 |
| CA Canada | Health Canada | 9 | March 11, 2026 |
| EU European Union | EMA | 1 | May 19, 2026 |
GBUnited Kingdom· MHRA
14 products
Uses
1). In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
How to take
CACanada· Health Canada
9 products
Uses
03/2024 4 DOSAGE AND ADMINISTRATION 03/2024 7 WARNINGS AND PRECAUTIONS 03/2024 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ..........................................................................................
2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................
4 1 INDICATIONS ............................................................................................................. 1 Pediatrics................................................................................................................
2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................
EUEuropean Union· EMA
1 product
Uses
1). In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
How to take
Drug interactions
Known interactions involving Palbociclib. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 263. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000571699 · revised February 27, 2026
- [2]Health Canada (DPD) · 02493535 · revised July 31, 2025
- [3]European Medicines Agency · EMEA/H/C/003853 · revised May 19, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.